The economics of diseases and cures /Randall Waechter, PhD, Associate Director of Research, Assistant Dean School of Graduate Studies, and Associate Professor School of Medicine, St. George's University, West Indies, editor.
The economics of diseases and cures /Randall Waechter, PhD, Associate Director of Research, Assistant Dean School of Graduate Studies, and Associate Professor School of Medicine, St. George's University, West Indies, editor.
- 1 online resource.
- Economic Issues, Problems and Perspectives Ser. .
Includes bibliographies and index.
Intro -- Contents -- Foreword -- Acknowledgments -- List of Acronyms -- Section A. Background and Measures -- Chapter 1 -- The Economics of Diseases and Cures -- Different Levels of Cures: Functional vs. Definitive -- Measuring the Economic Impact of Cures: Cost Strategy vs. Cures Strategy -- The Diffusion of Cures -- The Value of Case Studies -- References -- Chapter 2 -- Tools and Assumptions -- Data Sources -- Timelines -- Disease Categorization -- Cure Categorization -- Measures used to Assess the Value of Cures -- Years of Potential Life Lost (YPLL) -- Quality-Adjusted Life Years (QALY) Disability-Adjusted Life Years (DALY) -- Cure Impact -- Calculation Assumptions -- References -- Section B. Infectious Diseases -- Chapter 3 -- Acquired Immunodeficiency Syndrome (AIDS/HIV) -- Disease Category -- Disease Identification, Description, and Diagnostic Criteria -- Disease Etiology (Cause) -- Current Prevalence/Incidence -- Estimated Undiagnosed and At-Risk -- Disease Impact -- Years of Potential Life Lost (YPLL) -- Disease Impact -- Disability Adjusted Life Years (DALY) -- History of the Disease and Breakthroughs -- Current Cure Status -- Future Cure Obstacles Research Development and Treatment Costs -- HIV Cures: Anti-Retroviral Therapy (ART) -- Cure Category -- Cure Identification/Description -- Cure History -- Cure Science: Breakthroughs/Obstacles -- Cure Science: Future Obstacles -- Number of Patients Currently Being Treatment -- Number of Patients Requiring Treatment -- Impact of Treatment on Years of Potential Life Lost (YPLL) -- Impact of Treatment on Disability-Adjusted Life Years (DALY/QALY) -- Cost of Treatment Using ART per Patient -- Cost of Lifetime Treatment Using ART -- Economic Impact -- Value of Life Added -- HIV Cures -- Vaccination Cure Category -- Cure History -- Cure Science/Cure Obstacles -- Phase I Trials -- Phase II Trials -- Phase III Trials -- References -- Chapter 4 -- Influenza -- Disease Category -- Disease Description, Diagnosis, and Background -- Disease Etiology (Cause) -- Current Prevalence/Incidence -- Estimated Undiagnosed/At-Risk -- Disease Impact -- Years of Potential Life Lost (YPLL) -- Disease Impact -- Disability Adjusted Life Years (DALY) -- History of the Disease and Breakthroughs -- Current Cure Status -- Research, Development and Treatment Costs -- Influenza Cures: Vaccinations -- Cure Category Cure Identification/Description -- Cure History -- Cure Science: Breakthroughs/Obstacles -- Cure Science/Future Cure Obstacles and Targets -- Number of Patients Currently Being Treated -- Number of People Requiring Treatment -- Impact of Treatment on Years of Potential Life Lost (YPLL) -- Impact of Treatment on Disability-adjusted Life Years (DALY/QALY) -- Average Annual Total/Lifetime Cost of Vaccinations -- Economic Impact -- Value of Life Added -- Economic Impact -- Value of Reduction in DALYs/Increase in QALYs -- Influenza Cures: Antivirals -- Cure Category -- Cure Identification/Description
"This book examines the process of cure discovery and the economic impact of cures across varying diseases. It is the first time anyone has attempted to examine the [economic] returns across a wide spectrum of disease categories, using a common frame of reference"--
9781536196146
2021018520
Medical economics.
Electronic Books.
R728 / .E266 2021
Includes bibliographies and index.
Intro -- Contents -- Foreword -- Acknowledgments -- List of Acronyms -- Section A. Background and Measures -- Chapter 1 -- The Economics of Diseases and Cures -- Different Levels of Cures: Functional vs. Definitive -- Measuring the Economic Impact of Cures: Cost Strategy vs. Cures Strategy -- The Diffusion of Cures -- The Value of Case Studies -- References -- Chapter 2 -- Tools and Assumptions -- Data Sources -- Timelines -- Disease Categorization -- Cure Categorization -- Measures used to Assess the Value of Cures -- Years of Potential Life Lost (YPLL) -- Quality-Adjusted Life Years (QALY) Disability-Adjusted Life Years (DALY) -- Cure Impact -- Calculation Assumptions -- References -- Section B. Infectious Diseases -- Chapter 3 -- Acquired Immunodeficiency Syndrome (AIDS/HIV) -- Disease Category -- Disease Identification, Description, and Diagnostic Criteria -- Disease Etiology (Cause) -- Current Prevalence/Incidence -- Estimated Undiagnosed and At-Risk -- Disease Impact -- Years of Potential Life Lost (YPLL) -- Disease Impact -- Disability Adjusted Life Years (DALY) -- History of the Disease and Breakthroughs -- Current Cure Status -- Future Cure Obstacles Research Development and Treatment Costs -- HIV Cures: Anti-Retroviral Therapy (ART) -- Cure Category -- Cure Identification/Description -- Cure History -- Cure Science: Breakthroughs/Obstacles -- Cure Science: Future Obstacles -- Number of Patients Currently Being Treatment -- Number of Patients Requiring Treatment -- Impact of Treatment on Years of Potential Life Lost (YPLL) -- Impact of Treatment on Disability-Adjusted Life Years (DALY/QALY) -- Cost of Treatment Using ART per Patient -- Cost of Lifetime Treatment Using ART -- Economic Impact -- Value of Life Added -- HIV Cures -- Vaccination Cure Category -- Cure History -- Cure Science/Cure Obstacles -- Phase I Trials -- Phase II Trials -- Phase III Trials -- References -- Chapter 4 -- Influenza -- Disease Category -- Disease Description, Diagnosis, and Background -- Disease Etiology (Cause) -- Current Prevalence/Incidence -- Estimated Undiagnosed/At-Risk -- Disease Impact -- Years of Potential Life Lost (YPLL) -- Disease Impact -- Disability Adjusted Life Years (DALY) -- History of the Disease and Breakthroughs -- Current Cure Status -- Research, Development and Treatment Costs -- Influenza Cures: Vaccinations -- Cure Category Cure Identification/Description -- Cure History -- Cure Science: Breakthroughs/Obstacles -- Cure Science/Future Cure Obstacles and Targets -- Number of Patients Currently Being Treated -- Number of People Requiring Treatment -- Impact of Treatment on Years of Potential Life Lost (YPLL) -- Impact of Treatment on Disability-adjusted Life Years (DALY/QALY) -- Average Annual Total/Lifetime Cost of Vaccinations -- Economic Impact -- Value of Life Added -- Economic Impact -- Value of Reduction in DALYs/Increase in QALYs -- Influenza Cures: Antivirals -- Cure Category -- Cure Identification/Description
"This book examines the process of cure discovery and the economic impact of cures across varying diseases. It is the first time anyone has attempted to examine the [economic] returns across a wide spectrum of disease categories, using a common frame of reference"--
9781536196146
2021018520
Medical economics.
Electronic Books.
R728 / .E266 2021